Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
REGENERX BIOPHARMACEUTICALS INC (RGRX)
|
Add to portfolio |
|
|
|
| Price: |
$0.16
| | Metrics |
| OS: |
143.5
|
M
| |
|
|
| Market cap: |
$23
|
M
| |
|
|
|
Net cash:
|
$478.4
|
k
| |
$0.00
|
per share
|
|
EV:
|
$22.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($1.5)
|
M
| |
|
|
|
EBIT
|
($1.5)
|
M
| |
|
|
| EPS |
($0.01)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 08/14/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 08/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events Interactive Data |
| 07/11/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 07/06/2023 |
SC 13D/A
| SIGMA TAU FINANZIARIA SPA reports a 36.1% stake in RegeneRx Biopharmaceuticals, Inc. |
| 07/06/2023 |
4
| Essetifin SPA (10% Owner) has filed a Form 4 on REGENERX BIOPHARMACEUTICALS INC |
| 04/03/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Revenue growth | 0.0% | 0.0% | 10.2% | 23.0% | -39.3% | 53.9% | | -100.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Research and development | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.4 |
| General and administrative | 1.4 | 1.4 | 1.3 | 1.3 | 1.4 | 1.5 | 1.6 | 1.2 |
| EBIT | -1.3 | -1.3 | -1.3 | -1.3 | -1.4 | -1.7 | -1.7 | -1.6 |
| EBIT margin | -1730.7% | -1686.5% | -1643.9% | -1899.6% | -2550.0% | -1794.1% | -2820.5% | |
| Pre-tax income | -1.6 | -1.5 | -1.4 | -2.0 | 0.4 | 0.2 | -5.3 | -2.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 25.6% | 0.0% | 0.0% | 0.0% |
| Net income | -1.6 | -1.5 | -1.5 | -2.0 | 0.3 | 0.2 | -5.3 | -2.8 |
| Net margin | -2081.5% | -1984.6% | -1936.9% | -2861.5% | 505.7% | 245.6% | -8695.4% | |
| |
| Diluted EPS | ($0.01) | ($0.01) | ($0.01) | ($0.02) | $0.00 | $0.00 | ($0.05) | ($0.03) |
| Shares outstanding (diluted) | 138.6 | 133.4 | 131.0 | 120.7 | 120.9 | 125.9 | 101.5 | 93.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|